PatientsVille.com Logo


Heart Attack Medical Research Studies

Up-to-date List of Heart Attack Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Heart Attack Medical Research Studies

Rank Status Study
1 Recruiting China Acute Myocardial Infarction Registry
Condition: Acute Myocardial Infarction
Outcome Measures: In-hospital mortality of the patients with acute myocardial infarction in different-level hospitals across China;   The rate of the application of thrombolysis and primary percutaneous coronary intervention for Chinese patients with acute myocardial infarction in different-level hospitals;   provoking factors of Chinese patients with AMI across different areas and different population in China
2 Recruiting Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
Condition: ST-elevation Myocardial Infarction
Interventions: Drug: Mineralocorticoid receptor antagonist potassium-canrenoate;   Drug: placebo
Outcome Measures: Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging;   Markers of myocardial reperfusion injury;   Microvascular obstruction on cardiac MRI;   Myocardial salvage;   Acute myocardial infarct size;   LV remodelling;   Clinical outcome measures
3 Recruiting MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction
Condition: Myocardial Infarction
Intervention: Genetic: Blood sample
Outcome Measure: Correlation phenotype/genotype of sudden death at the acute phase of myocardial infarct.
4 Recruiting Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
Conditions: Coronary Artery Disease;   Acute Myocardial Infarction With ST-segment Elevation;   Primary Percutaneous Coronary Intervention;   Early Discharge
Interventions: Other: Early discharge;   Other: Standard discharge
Outcome Measures: • Composite of incidence of death, reinfarction, unstable angina pectoris, stroke, unplanned rehospitalization, repeat target vessel revascularization and stent thrombosis in 30 days after myocardial infarction (MI);   Composite of incidence of death, reinfarction, unstable angina pectoris, stroke, unplanned rehospitalization, repeat target vessel revascularization and stent thrombosis in 90 days after MI;   Complications associated with the puncture site requiring treatment in 30 days after myocardial infarction (MI)
5 Not yet recruiting Angiogenesis and Fibrosis in Myocardial Infarction
Conditions: Myocardial Infarction;   Fibrosis;   Neovascularization, Pathologic
Interventions: Procedure: Cardiac MRI scan;   Radiation: CT-PET scan;   Radiation: CT-coronary angiogram
Outcome Measures: The primary outcome is heart function determined by ejection fraction (in %) 6 months following a Heart Attack.;   Extent of fibrosis (% late gadolinium enhancement) & blood flow 6 months post-MI, and the correlation with integrin expression at 9 weeks (fluciclatide distribution through the myocardium viewed on CTPET images).
6 Unknown  Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
Condition: Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).
Interventions: Drug: Exenatide infusion;   Drug: Placebo infusion.
Outcome Measures: Safety of GLP-1 receptor agonist Exenatide infusion compared to placebo in patients with an acute myocardial infarction undergoing primary PCI;   Infarct size, assessed by means of the final infarct size at 4 months post myocardial infarction (CMRI) as a percentage of the area at risk at 1 week post myocardial infarction (T2 weighed CMRI).;   Regional myocardial function based on a MRI segmental analysis at 1 weeek and at 4 months post myocardial infarction.;   Global left ventricular ejection fraction (EF), Left Ventricular End Systolic Volume (LVESV), Left Ventricular End Diastolic Volume (LVEDV) at 1 week and at 4 months post myocardial infarction measured by Cardiac MRI.;   Regional myocardial function assessed by 2D and 3D echocardiography at 1 week and at 4 months post myocardial infarction.;   Global left ventricular EF, LVESV, LVEDV at 1 week and at 4 months post myocardial infarction measured by 2D and 3D echocardiography.;   Angiographic parameters as Trombolysis In Myocardial Infarction (TIMI) frame count and TIMI blush grade after PCI.;   The occurrence within 4 months of a Major Adverse Cardiac Event (MACE) defined as cardiac death, myocardial infarction, coronary bypass grafting, or a repeat PCI .;   Side effects of exenatide;   Serum-glucose levels during the first 72 hours.
7 Not yet recruiting Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?
Condition: ST-Elevation Myocardial Infarction
Intervention: Device: Life Recovery Systems ThermoSuit
Outcome Measures: Feasibility of use of cooling device as determined by ability and time to achieve target temperature and ease of maintaining temperature in therapeutic range (32 to 34°C) for three hours following removal of patient from ThermoSuit.;   Primary safety endpoint: composite of serious adverse events including: death, re-infarction, ischemia-driven TVR, pneumonia, sepsis, arrhythmia, bleeding, stroke, and renal failure.;   Major adverse cardiac events at 30 days as defined by death or non-fatal re-infarction. c. Ischemia-driven target vessel revascularization.;   Myocardial infarct size at 30 days as measured by 99mTc-sestamibi SPECT imaging.;   Safety, including all-cause mortality, cardiac, vascular, and hematological complications.;   Adverse events associated with conscious sedation.;   Arterial blood pressure and heart rate every 5 minutes from the baseline just before the start of cooling until 30 minutes after cooling has started.;   Door to balloon time.
8 Recruiting Safety of Early Discharge Following Low Risk Myocardial Infarction
Condition: Myocardial Infarction
Interventions: Other: early discharge (<72 h);   Other: Conventional discharge
Outcome Measures: All cause mortality, new acute myocardial infarction, new unstable angina, heart failure, ventricular arrhythmias, stroke and severe bleeding.;   All cause mortality;   Myocardial infarction;   Unstable angina;   Heart failure;   Ventricular arrhythmias;   Stroke;   Severe bleeding
9 Recruiting Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease
Conditions: Myocardial Infarction;   Angioplasty, Transluminal, Percutaneous Coronary;   Echocardiography, Stress
Interventions: Procedure: complete multivessel revascularization;   Procedure: stress echocardiography and revascularization if required
Outcome Measures: Combined event of cardiovascular death/re-myocardial infarction/revascularization of any vessel/admission due to heart failure;   Incidence of acute renal failure (contrast induced nephropathy);   Cost analysis of both strategies;   Death;   re-myocardial infarction;   revascularization of any vessel;   admission due to heart failure
10 Recruiting Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction
Conditions: Coronary Artery Disease;   Myocardial Infarction
Intervention: Procedure: Primary Percutaneous Coronary Intervention
Outcome Measures: Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance;   Myocardial infarct size expressed as a percentage to the myocardium at risk determined by Cardiac Magnetic Resonance
11 Unknown  Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction
Condition: Myocardial Infarction
Interventions: Drug: Etanercept;   Drug: saline
Outcome Measures: Composite of major adverse cardiovascular events (MACE) consisting of cardiovascular death, fatal myocardial infarction and fatal stroke;   Composite endpoint of major cardiovascular events, non-elective coronary revascularization procedures and hospitalization for unstable angina Cardiovascular death Non-fatal myocardial infarction Non-fatal stroke of all classifications;   Elevation of ALT, AST and CK;   serum adiponectin concentration, activity and isoforms
12 Unknown  Erythropoietin in Acute Myocardial Infarction
Condition: Acute Myocardial Infarction
Intervention: Drug: Erythropoietin
Outcome Measures: Myocardial infarct size;   Death;   Reinfarction
13 Unknown  Frailty as an INstrument for Evaluation of Elderly Patients With Non ST Elevation Myocardial Infarction (NSTEMI)
Conditions: Non-ST Elevation Myocardial Infarction (NSTEMI);   Frailty
Outcome Measures: The composite of death from any cause, myocardial infarction, revascularization due to ischemia, hospitalization from any cause, major bleeding, stroke/TIA and need for dialysis by one month after inclusion.;   The composite of major bleeding, stroke/TIA and need for dialysis by one month after inclusion.
14 Recruiting BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction
Conditions: Myocardial Infarction;   Death
Intervention: Procedure: Bone Marrow aspiration and intracoronary reinfusion
Outcome Measures: Time from randomization to all-cause death;   Time from randomization to cardiac death;   time from randomization to cardiovascular rehospitalisation;   incidence and severity of adverse events;   bleeding by BARC definition
15 Recruiting Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
Conditions: Acute Myocardial Infarction (AMI);   Acute Coronary Syndrome (ACS);   ST Elevation (STEMI) Myocardial Infarction;   Ischemic Reperfusion Injury;   Non-ST Elevation (NSTEMI) Myocardial Infarction;   Angina, Unstable
Intervention: Drug: Oxygen
Outcome Measure: Plasma concentration levels over time of biomarkers of oxidative stress, apoptosis, inflammation and platelet aggregation
16 Recruiting REgister of Myocardial Infarction Patients Treated by the NOVAra STE-MI Network
Condition: Acute Myocardial Infarction
Intervention: Device: Primary PCI
Outcome Measures: Successful reperfusion;   In Hospital Cardiac Mortality;   In hospital myocardial infarction;   In hospital stent thrombosis
17 Recruiting Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction
Conditions: Myocardial Infarction;   Heart Failure;   Myocardial Revascularization;   Atrial Fibrillation
Interventions: Drug: Pikasol;   Other: Corn oil
Outcome Measures: Combined total mortality, first event of non-fatal myocardial infarction, stroke and revascularization.;   Occurence of new onset atrial fibrillation
18 Not yet recruiting Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction
Conditions: Myocardial Infarction;   Heart Failure;   Coronary Artery Disease
Intervention: Other: Secondary prevention and cardiac rehabilitation clinic
Outcome Measures: Lymphocyte GRK2 mRNA level;   Left ventricular systolic function;   Left ventricular dimensions;   Plasma epinephrine;   heart rate variability;   exercise capacity (VO2max);   ambulatory blood pressure;   Plasma brain natriuretic peptide;   Maximal cardiac output and stroke volume using electrical bioimpedance;   lymphocyte GRK2 protein levels
19 Recruiting Effect of Remote Ischemic Conditioning in Heart Attack Patients
Condition: ST-segment Elevation Myocardial Infarction (STEMI)
Interventions: Device: Remote ischemic conditioning;   Device: Control
Outcome Measures: Myocardial infarct size;   Acute kidney injury
20 Recruiting Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack
Conditions: Heart Failure;   Myocardial Infarction
Interventions: Drug: mecasermin;   Drug: 0.9% sodium chloride injection
Outcome Measures: Serum glucose measurement;   Percent change in global left ventricular ejection fraction (LVEF) measured by quantitative cardiac magnetic resonance imaging (MRI)

These studies may lead to new treatments and are adding insight into Heart Attack etiology and treatment.

A major focus of Heart Attack research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Heart Attack